The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Shi, Rui ^a   Zhou, Xin ^a   Ji, Wen Jie ^a   Zhang, Ying Ying ^a   Ma, Yong Qiang ^a   Zhang, Jian Qi ^a   Li, Yu Ming ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CCAAT ENHANCER BINDING PROTEIN; MICRORNA 223; PURINERGIC P2Y RECEPTOR ANTAGONIST; RNA BINDING PROTEIN; MICRORNA; MIRN223 MICRORNA, HUMAN; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR;

BIOGENESIS; CELL DIFFERENTIATION; CELL LOSS; CELL STRESS; DNA DAMAGE; GENE FUNCTION; GENETIC CODE; HUMAN; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PLATELET REACTIVITY; REGULATOR GENE; REVIEW; RNA TRANSLATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; CORONARY DISEASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MEGAKARYOCYTE; METABOLISM; PATHOLOGY; THROMBOCYTE;

BLOOD PLATELETS; CORONARY DISEASE; GENE EXPRESSION REGULATION; HUMANS; MEGAKARYOCYTES; MICRORNAS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2Y12;

EID: 84937010386     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/981841     Document Type: Review

References (94)

1. R. C. Lee, R. L. Feinbaum, and V. Ambros, "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14," Cell, vol. 75, no. 5, pp. 843-854, 1993.
2. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281-297, 2004.
3. F. Taïbi, V. Metzinger-LeMeuth, Z. A. Massy, and L. Metzinger, "MiR-223: an inflammatory oncomiR enters the cardiovascular field," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1842, no. 7, pp. 1001-1009, 2014.
4. R. C. Friedman, K. K.-H. Farh, C. B. Burge, and D. P. Bartel, "Most mammalian mRNAs are conserved targets of microRNAs," Genome Research, vol. 19, no. 1, pp. 92-105, 2009.
5. B. P. Lewis, C. B. Burge, and D. P. Bartel, "Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets," Cell, vol. 120, no. 1, pp. 15-20, 2005.
6. W. P. Kloosterman and R. H. A. Plasterk, "The diverse functions of microRNAs in animal development and disease," Developmental Cell, vol. 11, no. 4, pp. 441-450, 2006.
7. G. C. Shukla, J. Singh, and S. Barik, "MicroRNAs: processing, maturation, target recognition and regulatory functions," Molecular and Cellular Pharmacology, vol. 3, no. 3, pp. 83-92, 2011.
8. D. P. Bartel, "MicroRNAs: target recognition and regulatory functions," Cell, vol. 136, no. 2, pp. 215-233, 2009.
9. E. Wienholds, W. P. Kloosterman, E. Miska et al., "MicroRNA expression in zebrafish embryonic development," Science, vol. 309, no. 5732, pp. 310-311, 2005.
10. J. D. Port and C. Sucharov, "Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials," Journal of Cardiovascular Pharmacology, vol. 56, no. 5, pp. 444-453, 2010.
11. M. S. Jamaluddin, S. M. Weakley, L. Zhang et al., "MiRNAs: roles and clinical applications in vascular disease," Expert Review of Molecular Diagnostics, vol. 11, no. 1, pp. 79-89, 2011.
12. C. Urbich, A. Kuehbacher, and S. Dimmeler, "Role of microRNAs in vascular diseases, inflammation, and angiogenesis," Cardiovascular Research, vol. 79, no. 4, pp. 581-588, 2008.
13. N. Nouraee and G. A. Calin, "MicroRNAs as cancer biomarkers," MicroRNA, vol. 2, no. 2, pp. 102-117, 2013.
14. L. Tutar, E. Tutar, and Y. Tutar, "MicroRNAs and cancer; an overview," Current Pharmaceutical Biotechnology, vol. 15, no. 5, pp. 430-437, 2014.
15. Y. Lee, C. Ahn, J. Han et al., "The nuclear RNase III Drosha initiates microRNA processing," Nature, vol. 425, no. 6956, pp. 415-419, 2003.
16. H. Zhang, F. A. Kolb, L. Jaskiewicz, E. Westhof, and W. Filipowicz, "Single processing center models for human Dicer and bacterial RNase III," Cell, vol. 118, no. 1, pp. 57-68, 2004.
17. J. Han, Y. Lee, K.-H. Yeom, Y.-K. Kim, H. Jin, and V. N. Kim, "The Drosha-DGCR8 complex in primary microRNA processing," Genes & Development, vol. 18, no. 24, pp. 3016-3027, 2004.
18. T. P. Chendrimada, R. I. Gregory, E. Kumaraswamy et al., "TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing," Nature, vol. 436, no. 7051, pp. 740-744, 2005.
19. S. Cheloufi, C. O. Dos Santos, M. M. W. Chong, and G. J. Hannon, "Adicer-independent miRNA biogenesis pathway that requires Ago catalysis," Nature, vol. 465, no. 7298, pp. 584-589, 2010.
20. D. Cifuentes, H. Xue, D. W. Taylor et al., "A novel miRNA processing pathway independent of dicer requires argonaute2 catalytic activity," Science, vol. 328, no. 5986, pp. 1694-1698, 2010.
21. S. Muller and K. Nowak, "Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by nextgeneration sequencing expression profiles," BioMed Research International, vol. 2014, Article ID 948408, 11 pages, 2014.
22. S.-Y. Ying, D. C. Chang, and S.-L. Lin, "The MicroRNA (miRNA): overview of the RNA genes that modulate gene function," Molecular Biotechnology, vol. 38, no. 3, pp. 257-268, 2008.
23. A. Kozomara and S. Griffiths-Jones, "MiRBase: integrating microRNA annotation and deep-sequencing data," Nucleic Acids Research, vol. 39, no. 1, pp. D152-D157, 2011.
24. S. Griffiths-Jones, "miRBase, microRNA sequences and annotation," in Current Protocols in Bioinformatics, A. D. Baxevanis et al., Ed., Chapter 12, 2010.
25. M. R. Fabian, T. R. Sundermeier, and N. Sonenberg, "Understanding how miRNAs post-transcriptionally regulate gene expression," Progress in Molecular and Subcellular Biology, vol. 50, pp. 1-20, 2010.
26. A. E. Rodriguez, J. A. Hernandez, R. Benito et al., "Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14," PloS ONE, vol. 17, no. 11, Article ID e48485, 2012.
27. J. B. Johnnidis, M. H. Harris, R. T. Wheeler et al., "Regulation of progenitor cell proliferation and granulocyte function by microRNA-223," Nature, vol. 451, no. 7182, pp. 1125-1129, 2008.
28. C.-Z. Chen, L. Li, H. F. Lodish, and D. P. Bartel, "MicroRNAs modulate hematopoietic lineage differentiation," Science, vol. 303, no. 5654, pp. 83-86, 2004.
29. K. Kapinas and A. M. Delany, "MicroRNA biogenesis and regulation of bone remodeling," Arthritis Research and Therapy, vol. 13, no. 3, article 220, 2011.
30. F. Fazi, A. Rosa, A. Fatica et al., "A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis," Cell, vol. 123, no. 5, pp. 819-831, 2005.
31. G. Zardo, A. Ciolfi, L. Vian et al., "Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression," Blood, vol. 119, no. 17, pp. 4034-4046, 2012.
32. G. Zhuang, C. Meng, X. Guo et al., "A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation," Circulation, vol. 125, no. 23, pp. 2892-2903, 2012.
33. R. M.O'Connell, J. L. Zhao, and D. S. Rao, "MicroRNA function in myeloid biology," Blood, vol. 118, no. 11, pp. 2960-2969, 2011.
34. T. Li, M. J. Morgan, S. Choksi, Y. Zhang, Y.-S. Kim, and Z.-G. Liu, "MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiation," Nature Immunology, vol. 11, no. 9, pp. 799-805, 2010.
35. N. Ismail, Y. Wang, D. Dakhlallah et al., "Macrophage microvesicles induce macrophage differentiation and miR-223 transfer," Blood, vol. 121, no. 6, pp. 984-995, 2013.
36. Y.-H. Yu, L. Zhang, D.-S. Wu et al., "MiR-223 regulates human embryonic stem cell differentiation by targeting the IGF-1R/Akt signaling pathway," PLoS ONE, vol. 8, no. 11, Article ID e78769, 2013.
37. L. Shi, B. Fisslthaler, N. Zippel et al., "MicroRNA-223 antagonizes angiogenesis by targeting β1 integrin and preventing growth factor signaling in endothelial cells," Circulation Research, vol. 113, no. 12, pp. 1320-1330, 2013.
38. R. Seifeddine, A. Dreiem, E. Blanc et al., "Hypoxia downregulates CCAAT/enhancer binding protein-α expression in breast cancer cells," Cancer Research, vol. 68, no. 7, pp. 2158-2165, 2008.
39. M. Eyholzer, S. Schmid, J. A. Schardt, S. Haefliger, B.U. Mueller, and T. Pabst, "Complexity of miR-223 regulation by CEBPA in human AML," Leukemia Research, vol. 34, no. 5, pp. 672-676, 2010.
40. M. K. Zeman and K. A. Cimprich, "Causes and consequences of replication stress," Nature Cell Biology, vol. 16, no. 1, pp. 2-9, 2014.
41. G. Wan, R. Mathur, X. Hu, X. Zhang, and X. Lu, "miRNA response to DNA damage," Trends in Biochemical Sciences, vol. 36, no. 9, pp. 478-484, 2011.
42. M. M. Streppel, S. Pai, N. R. Campbell et al., "MicroRNA 223 is upregulated in the multistep progression of barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1," Clinical Cancer Research, vol. 19, no. 15, pp. 4067-4078, 2013.
43. M. Durik, M. Kavousi, I. Van Der Pluijm et al., "Nucleotide excision DNA repair is associated with age-related vascular dysfunction," Circulation, vol. 126, no. 4, pp. 468-478, 2012.
44. I. Gorenne, S. Kumar, K. Gray et al., "Vascular smooth muscle cell sirtuin 1 protects against dna damage and inhibits atherosclerosis," Circulation, vol. 127, no. 3, pp. 386-396, 2013.
45. T. Sugatani and K. A. Hruska, "MicroRNA-223 is a key factor in osteoclast differentiation," Journal of Cellular Biochemistry, vol. 101, no. 4, pp. 996-999, 2007.
46. E. M. Pinatel, F. Orso, E. Penna et al., "miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions," PLoS ONE, vol. 9, no. 1, Article ID e84859, 2014.
47. X. Li, Y. Zhang, H. Zhang et al., "miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3," Molecular Cancer Research, vol. 9, no. 7, pp. 824-833, 2011.
48. A. Laios, S.O'Toole, R. Flavin et al., "Potential role of miR-9 and miR-223 in recurrent ovarian cancer," Molecular Cancer, vol. 7, article 35, 2008.
49. M. Haneklaus, M. Gerlic, L. A. J. O'Neill, and S. L. Masters, "MiR-223: infection, inflammation and cancer," Journal of Internal Medicine, vol. 274, no. 3, pp. 215-226, 2013.
50. + adipose tissue macrophages are associated with insulin resistance in human obesity," Diabetes, vol. 59, no. 7, pp. 1648-1656, 2010.
51. Z.-X. Meng, G.-X. Wang, and J. D. Lin, "A MicroRNA circuitry links macrophage polarization to metabolic homeostasis," Circulation, vol. 125, no. 23, pp. 2815-2817, 2012.
52. M. C. Lu, C. L. Yu, H. C. Chen et al., "Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production," Clinical and Experimental Immunology, vol. 177, no. 3, pp. 641-651, 2014.
53. S. Gosavi and D. Mukherjee, "Review of newer anticoagulants and anti-platelet agents in acute coronary syndrome and cardiovascular diseases," Cardiovascular & Hematological Agents in Medicinal Chemistry, vol. 11, no. 3, pp. 194-202, 2013.
54. H. Jneid, J. L. Anderson, R. S. Wright et al., "2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Journal of the American College of Cardiology, vol. 60, no. 7, pp. 645-681, 2012.
55. D. Trenk, S. D. Kristensen, W. Hochholzer, and F.-J. Neumann, "High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials," Thrombosis and Haemostasis, vol. 109, no. 5, pp. 834-845, 2013.
56. U. S. Tantry, L. Bonello, D. Aradi et al., "Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding," Journal of the American College of Cardiology, vol. 62, no. 24, pp. 2261-2273, 2013.
57. D. Aradi, A. Komócsi, A. Vorobcsuk et al., "Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and metaanalysis," American Heart Journal, vol. 160, no. 3, pp. 543-551, 2010.
58. N. J. Breet, J. W. Van Werkum, H. J. Bouman et al., "High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention," Heart, vol. 97, no. 12, pp. 983-990, 2011.
59. J. Miao, R. Liu, and Z. Li, "Cytochrome P-450 polymorphisms and response to clopidogrel," The New England Journal of Medicine, vol. 360, no. 21, pp. 2250-2251, 2009.
60. C. H. Ts'ao, "Rough endoplasmic reticulum and ribosomes in blood platelets," Scandinavian Journal of Haematology, vol. 8, no. 2, pp. 134-140, 1971.
61. + RNA," Biochemical and Biophysical Research Communications, vol. 160, no. 2, pp. 705-710, 1989.
62. P. Bugert, A. Dugrillon, A. Günaydin, H. Eichler, and H. Klüter, "Messenger RNA profiling of human platelets by microarray hybridization," Thrombosis and Haemostasis, vol. 90, no. 4, pp. 738-748, 2003.
63. D. V. Gnatenko, J. J. Dunn, J. Schwedes, and W. F. Bahou, "Transcript profiling of human platelets using microarray and serial analysis of gene expression (SAGE)," Methods in Molecular Biology, vol. 496, pp. 245-272, 2009.
64. J. P. McRedmond, S. D. Park, D. F. Reilly et al., "Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes," Molecular & Cellular Proteomics, vol. 3, no. 2, pp. 133-144, 2004.
65. P. Landry, I. Plante, D. L. Ouellet, M. P. Perron, G. Rousseau, and P. Provost, "Existence of a microRNA pathway in anucleate platelets," Nature Structural and Molecular Biology, vol. 16, no. 9, pp. 961-966, 2009.
66. T. Höchtl and K. Huber, "P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes," Hamostaseologie, vol. 34, no. 1, pp. 20-28, 2014.
67. S. Nagalla, C. Shaw, X. Kong et al., "Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity," Blood, vol. 117, no. 19, pp. 5189-5197, 2011.
68. A.A. Kondkar, M. S. Bray, S.M. Leal et al., "VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA," Journal of Thrombosis and Haemostasis, vol. 8, no. 2, pp. 369-378, 2010.
69. R. Shi, L. Ge, X. Zhou et al., "Decreased plate let miR-223 expression is associated with high on-clopidogrel platelet reactivity," Thrombosis Research, vol. 131, no. 6, pp. 508-513, 2013.
70. A. R. Shuldiner, J. R. O'Connell, K. P. Bliden et al., "Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy," The Journal of the American Medical Association, vol. 302, no. 8, pp. 849-858, 2009.
71. J. M. Siller-Matula, I. Lang, G. Christ, and B. Jilma, "Calciumchannel blockers reduce the antiplatelet effect of clopidogrel," Journal of the American College of Cardiology, vol. 52, no. 19, pp. 1557-1563, 2008.
72. U. S. Tantry, D. J. Kereiakes, and P. A. Gurbel, "Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations," JACC: Cardiovascular Interventions, vol. 4, no. 4, pp. 365-380, 2011.
73. J. S. Berger, D. L. Bhatt, S. R. Steinhubl et al., "Smoking, clopidogrel, and mortality in patients with established cardiovascular disease," Circulation, vol. 120, no. 23, pp. 2337-2344, 2009.
74. L. Ang, V. Palakodeti, A. Khalid et al., "Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel," Journal of the American College of Cardiology, vol. 52, no. 13, pp. 1052-1059, 2008.
75. J. Silvain, G. Cayla, J.-S. Hulot et al., "High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIORPLATELET study," European Heart Journal, vol. 33, no. 10, pp. 1241-1250, 2012.
76. S. Fichtlscherer, A. M. Zeiher, and S. Dimmeler, "Circulating MicroRNAs: biomarkers or mediators of cardiovascular diseases?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 11, pp. 2383-2390, 2011.
77. R. A. Boon and K. C. Vickers, "Intercellular transport of MicroRNAs," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. 186-192, 2013.
78. P. Diehl, A. Fricke, L. Sander et al., "Microparticles: major transport vehicles for distinct microRNAs in circulation," Cardiovascular Research, vol. 93, no. 4, pp. 633-644, 2012.
79. A. Zampetaki, P. Willeit, L. Tilling et al., "Prospective study on circulating microRNAs and risk of myocardial infarction," Journal of the American College of Cardiology, vol. 60, no. 4, pp. 290-299, 2012.
80. ∗ microRNA complexes to endothelial cells via microparticles," Blood, vol. 122, no. 2, pp. 253-261, 2013.
81. P. Willeit, A. Zampetaki, K. Dudek et al., "Circulating MicroRNAs as novel biomarkers for platelet activation," Circulation Research, vol. 112, no. 4, pp. 595-600, 2013.
82. B. Aleil, C. Ravanat, J. P. Cazenave, G. Rochoux, A. Heitz, and C. Gachet, "Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases," Journal of Thrombosis and Haemostasis, vol. 3, no. 1, pp. 85-92, 2005.
83. A. M. Curtis and G. A. Fitzgerald, "Platelet microRNAs: novy mir∗ ormired in human complexity?" Circulation Research, vol. 112, no. 4, pp. 576-578, 2013.
84. Y.-Y. Zhang, X. Zhou, W.-J. Ji et al., "Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome," Journal of Thrombosis and Thrombolysis, vol. 38, no. 1, pp. 65-72, 2014.
85. K. Hussein, K. Theophile, W. Dralle, B. Wiese, H. Kreipe, and O. Bock, "MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia," Platelets, vol. 20, no. 6, pp. 391-400, 2009.
86. O. I. Petriv, F. Kuchenbauer, A. D. Delaney et al., "Comprehensive microRNA expression profiling of the hematopoietic hierarchy," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15443-15448, 2010.
87. H. Plé, P. Landry, A. Benham, C. Coarfa, P. H. Gunaratne, and P. Provost, "The repertoire and features of human platelet microRNAs," PLoS ONE, vol. 7, no. 12, Article IDe50746, 2012.
88. A. Osman and K. Fälker, "Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes," Platelets, vol. 22, no. 6, pp. 433-441, 2011.
89. P. F. Bray, S. E. McKenzie, L. C. Edelstein et al., "The complex transcriptional landscape of the anucleate human platelet," BMC Genomics, vol. 14, article 1, 2013.
90. S. Leierseder, T. Petzold, L. Zhang, X. Loyer, S. Massberg, and S. Engelhardt, "MiR-223 is dispensable for platelet production and function in mice," Thrombosis and Haemostasis, vol. 110, no. 6, pp. 1207-1214, 2013.
91. F. Bauernfeind, A. Rieger, F. A. Schildberg, P. A. Knolle, J. L. Schmid-Burgk, and V. Hornung, "NLRP3 inflammasome activity is negatively controlled by miR-223," Journal of Immunology, vol. 189, no. 8, pp. 4175-4181, 2012.
92. B.-S. Huang, Q.-Z. Luo, Y. Han, X.-B. Li, L.-J. Cao, and L.-X. Wu, "MicroRNA-223 promotes the growth and invasion of glioblastoma cells by targeting tumor suppressor PAX6," Oncology Reports, vol. 30, no. 5, pp. 2263-2269, 2013.
93. C. Y. Jia, H. H. Li, X. C. Zhu et al., "MiR-223 suppresses cell proliferation by targeting IGF-1R," PLoS ONE, vol. 6, no. 11, Article ID e27008, 2011.
94. B. Engelmann and S. Massberg, "Thrombosis as an intravascular effector of innate immunity," Nature Reviews Immunology, vol. 13, no. 1, pp. 34-45, 2013.